Amblyopia patients who used the CureSight treatment protocol “achieved greater improvements in visual acuity (VA) than those undergoing traditional occlusion therapy, or patching”, according to new research.
They were also more likely to adhere to the treatment regimen.
The multicentre randomised control trial (RCT) included 149 children with amblyopia who received either CureSight digitised binocular treatment or patching.
At the conclusion of the 16-week treatment period, the CureSight group achieved a mean improvement in distance VA of 2.8 lines, which was 0.53 lines higher than the patching group. Adherence rates were higher among CureSight users, with a median adherence rate of 94% compared to 83.9% in the patching group.
This study showing CureSight’s superiority over patching marks a major milestone in amblyopia treatment advancements
“This important breakthrough in amblyopia treatment is a reflection of NovaSight’s innovative technology in addition to the patients’ willingness to adhere to the CureSight regimen,” said Dr Tamara Wygnanski-Jaffe, lead author of the study.
“This study showing CureSight’s superiority over patching marks a major milestone in amblyopia treatment advancements and builds on previous peer-reviewed studies demonstrating CureSight’s non-inferiority to patching and preservation of visual gains,” said NovaSight CEO Ran Yam. CureSight is one of the flagship products for NovaSight, an Israeli company focussing on paediatric vision care.
The product has clearance from the United States Food and Drug Administration and the European CE Mark. It was recently granted Chinese approval.
Reference
- Wygnanski-Jaffe T, Kushner BJ, Moshkovitz A, Belkin M, Yehezkel O; CureSight Pivotal Trial Group. High-adherence dichoptic treatment versus patching in anisometropic and small angle strabismus amblyopia: a randomized controlled trial. Am J Ophthalmol. 2024 Aug 21:S0002-9394(24)00374-X. doi: 10.1016/j.ajo.2024.08.011. Epub ahead of print.